🔗 Share this article

The first new treatments for gonorrhoea in a generation are being described as a "huge turning point" in the fight against drug-resistant strains of the bacteria, according to scientists.

An International Challenge

Cases of gonorrhoea are increasing worldwide, with estimates suggesting more than 82 million new cases per year. Particularly high rates are reported in Africa and countries within the World Health Organization's Western Pacific region, which spans from Mongolia and China to New Zealand. Within England, cases have hit a record high, while rates across Europe in 2023 were three times higher compared to figures for 2014.

“The authorization of fresh medications for gonorrhoea is an significant and necessary advancement in the reality of growing infection rates, escalating drug resistance and the very limited available drugs at this time.”

Medical experts are deeply concerned about the surge in drug-resistant strains. The World Health Organization has classified it as a "high-priority threat". Ongoing monitoring found that the effectiveness of primary antibiotics like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

A Pair of Novel Therapies Secure Clearance

One new antibiotic, alternatively called Nuzolvence, was approved by the US Food and Drug Administration in December for treating gonorrhoea. This STI can lead to major issues, including the inability to conceive. Researchers anticipate that targeted use of this new drug will help hinder the development of resistance.

Another new antibiotic, originating from the pharmaceutical company GlaxoSmithKline, gained clearance in concurrent days. This treatment, which is additionally indicated for UTIs, was shown in trials to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Partnership

This new treatment stemmed from a innovative non-profit model for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the drug firm Innoviva to bring it to fruition.

“This authorization signifies a significant shift in the treatment of multidrug-resistant gonorrhoea, which until now has been staying ahead of medical innovation.”

Research Study Data and Global Access

According to findings detailed in a major medical journal, the new drug successfully treated over nine in ten of genital gonorrhoea infections. This establishes an similar efficacy with the typical regimen, which involves two antibiotics. The trial enrolled hundreds of participants from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its development partnership, GARDP has the authority to make available and distribute the drug in a wide range of regions with limited resources.

Clinicians treating patients have voiced positive views. Having a easy-to-administer therapy of this kind is seen as a "game-changer" for managing the epidemic. This is deemed essential to alleviate the strain of the illness for people and to halt the transmission of untreatable gonorrhoea globally.